-

Johnson & Johnson to Participate in the UBS MedTech, Tools and Genomics Summit

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the UBS MedTech, Tools and Genomics Summit on Tuesday, August 15th, at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Celine Martin, Company Group Chairman Cardiovascular & Specialty Solutions Group (CSS), Anthony (Tony) Long, VP, Clinical Research, Medical Affairs, Preclinical Research and Jasmina Brooks, President Biosense Webster will represent the Company in a session scheduled at 2:00 pm (Eastern Time).

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast replay will be available approximately 48-hrs after the live webcast.

Contacts

Investor Contact:
investor-relations@its.jnj.com

Media Contact:
media-relations@its.jnj.com

Industry:

Johnson & Johnson

NYSE:JNJ
Release Versions
English

Contacts

Investor Contact:
investor-relations@its.jnj.com

Media Contact:
media-relations@its.jnj.com

More News From Johnson & Johnson

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billion in Jacksonville, Florida to strengthen its Vision operations by scaling U.S.-based manufacturing, packaging and distribution capabilities. The investment includes construction of a new, state-of-the-art distribution facility, alongside advanced manufacturing and packaging technologies to exp...

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform for KRAS-driven tumors bolsters Johnson & Johnson’s oncology pipeline and ambition to develop targeted medicines for the most prevalent and hard-to-treat solid tumors with high un...

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’...
Back to Newsroom